Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02953457
Recruitment Status : Recruiting
First Posted : November 2, 2016
Last Update Posted : February 2, 2021
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Roswell Park Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 29, 2021
Estimated Study Completion Date : December 15, 2021